At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 303 enrolled
Drug / intervention
LEO 90100 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LEO 90100 in the Treatment of Psoriasis Vulgaris
In Brief
A Phase 2 clinical trial evaluating LEO 90100, Calcipotriol, and 1 other intervention for Psoriasis Vulgaris. Completed, enrolled 303 participants across 33 sites.
Detailed Summary
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartMay 2012
Primary CompletionSep 2012
Study CompletionNov 2012
TodayJul 2026
First PostedFeb 22, 2012
Enrollment StartMay 1, 2012
Primary CompletionSep 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.4 years ago
Interventions
LEO 90100drug
Calcipotrioldrug
Betamethasonedrug